These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29854293)

  • 1. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
    Itai S; Ohishi T; Kaneko MK; Yamada S; Abe S; Nakamura T; Yanaka M; Chang YW; Ohba SI; Nishioka Y; Kawada M; Harada H; Kato Y
    Oncotarget; 2018 Apr; 9(32):22480-22497. PubMed ID: 29854293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG
    Kaneko MK; Ohishi T; Kawada M; Kato Y
    Biochem Biophys Rep; 2020 Dec; 24():100826. PubMed ID: 33088928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.
    Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A defucosylated anti-PD-L1 monoclonal antibody 13-mG
    Takei J; Ohishi T; Kaneko MK; Harada H; Kawada M; Kato Y
    Biochem Biophys Rep; 2020 Dec; 24():100801. PubMed ID: 32923698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 47-mG
    Kaneko MK; Itai S; Yamada S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2018 Jun; 37(3):158-161. PubMed ID: 29630446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG
    Nanamiya R; Takei J; Ohishi T; Asano T; Tanaka T; Sano M; Nakamura T; Yanaka M; Handa S; Tateyama N; Harigae Y; Saito M; Suzuki H; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Feb; 41(1):1-7. PubMed ID: 35225663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2.
    Itai S; Yamada S; Kaneko MK; Sano M; Nakamura T; Yanaka M; Handa S; Hisamatsu K; Nakamura Y; Furusawa Y; Fukui M; Ohishi T; Kawada M; Harada H; Kato Y
    Biochem Biophys Rep; 2018 Sep; 15():93-96. PubMed ID: 30105309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Podocalyxin Monoclonal Antibody 47-mG
    Yamada S; Itai S; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):91-94. PubMed ID: 29649375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 134-mG
    Tateyama N; Nanamiya R; Ohishi T; Takei J; Nakamura T; Yanaka M; Hosono H; Saito M; Asano T; Tanaka T; Sano M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Aug; 40(4):177-183. PubMed ID: 34424762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG
    Kawabata H; Ohishi T; Suzuki H; Asano T; Kawada M; Suzuki H; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Dec; 41(6):320-327. PubMed ID: 35483055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
    Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
    Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defucosylated Monoclonal Antibody (H
    Suzuki H; Ohishi T; Nanamiya R; Kawada M; Kaneko MK; Kato Y
    Curr Issues Mol Biol; 2023 Sep; 45(10):7734-7748. PubMed ID: 37886932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
    Kaneko MK; Kunita A; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Ogasawara S; Ohishi T; Abe S; Itai S; Harada H; Kawada M; Nishioka Y; Fukayama M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):157-162. PubMed ID: 28665782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG
    Asano T; Tanaka T; Suzuki H; Li G; Ohishi T; Kawada M; Yoshikawa T; Kaneko MK; Kato Y
    Antibodies (Basel); 2022 Nov; 11(4):. PubMed ID: 36546899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Exerted Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor.
    Tanaka T; Ohishi T; Saito M; Suzuki H; Kaneko MK; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Jun; 41(3):142-149. PubMed ID: 35666554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.
    Ogasawara S; Kaneko MK; Yamada S; Honma R; Nakamura T; Saidoh N; Yanaka M; Yoshida K; Fujii Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):50-56. PubMed ID: 28384052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody.
    Goto N; Suzuki H; Ohishi T; Harakawa A; Li G; Saito M; Takei J; Tanaka T; Asano T; Sano M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):67-73. PubMed ID: 35377239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of critical epitope of PcMab-47 against human podocalyxin.
    Itai S; Yamada S; Kaneko MK; Kato Y
    Biochem Biophys Rep; 2018 Jul; 14():78-82. PubMed ID: 29872738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG
    Kawabata H; Suzuki H; Ohishi T; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):59-66. PubMed ID: 35471051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
    Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
    Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.